Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis.

CONCLUSION: This meta-analysis suggests that a 2/1 schedule of sunitinib lowers the risk of fatigue and the occurrence other AEs without compromising efficacy. PMID: 32975057 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32975057?dopt=Abstract

Source: Yonsei Medical Journal - September 27, 2020 Category: Universities & Medical Training Authors: Kang HJ, Lee S Tags: Yonsei Med J Source Type: research